MiR490's diagnostic capacity was demonstrated in various cancer kinds and diseases, adding to its clinical value

This miR‐490 review first illustrates its association with various clinical malignancies and other diseases. Although in various malignancies miR‐490's activities, regulatory mechanisms and targets were revealed, its significance to other illnesses is beginning to be studied. Note that miR‐490 levels are regulated at different levels by transcription factors, epigenetic factors, and ncRNAs, revealing complicated interplay between these components. A system approach that incorporates miR‐490 and its regulatory components will surely help detect critical miR‐490 hub connections that might affect tumor initiation/progression. Furthermore, a number of pharmacological and environmental variables known to cause disease have also been shown to alter miR‐490 levels, showing miR‐490's significant pathogenesis involvement. The fact that miR‐490 levels are strictly regulated and abnormal miR‐490 levels are reported in many cancer types and diseases highlights miR‐490's significance in controlling cell homeostasis.Due to their increased stability, miRNAs are developed as diagnostic agents. MiR‐490's diagnostic capacity was demonstrated in various cancer kinds and diseases, adding to its clinical value. The potential of miR‐490 as a non-invasive biomarker might possibly be studied by measuring patient serum/saliva/urine levels in tissues or body fluids. Furthermore, miR‐490's demonstrated ability to stratify healthy tissue tumor samples may aid establishing molecular diagnostic tools. In most circumstances, miR‐490's association with improved prognosis is also fascinating. This extra clinical importance makes miR‐490 appropriate for molecular therapy. In most cancer types where miR‐490 has been functionally identified, miR‐490 has been found to be a miRNA tumor suppressor that inhibits several cancer hallmarks by directly controlling oncogenic targets and pathways. In practical practice, a therapy regime using miR‐490 tissue alteration based on rapidly evolving targeted delivery methods may be on the horizon. Nevertheless, further in vivo investigations must be conducted using genetically changed mice models. Although miR‐490 was not yet clinically examined for its therapeutic potential, in vitro and in vivo preclinical experiments revealed enormous promise in translating miR‐490 as a novel therapeutic target. miR‐490 appears as a novel candidate miRNA with significant cancer diagnosis and therapy with its prognostic and diagnostic capabilities. Therefore, miR‐490 might serve as a novel weapon in the current anti-cancer treatment arsenal.